1
|
de Lima GV, Ferreira FDS. N-terminal-pro brain natriuretic peptides in dogs and cats: A technical and clinical review. Vet World 2017; 10:1072-1082. [PMID: 29062197 PMCID: PMC5639106 DOI: 10.14202/vetworld.2017.1072-1082] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Accepted: 08/18/2017] [Indexed: 01/16/2023] Open
Abstract
Biomarkers are quantitative indicators of biological processes performed by an organ or system. In recent years, natriuretic peptides (NPs) have emerged as important tools in the diagnosis and therapeutic monitoring of heart diseases. Research has shown that serum and plasma levels of N-terminal pro brain NP (NT-proBNP) in dogs and cats are the only biomarkers that afford to diagnose and monitor congestive processes and, indirectly, the myocardial function of small animals. The present review discusses the peer-reviewed specialized literature about NT-proBNP and presents and compares the potential clinical applications of this NP in veterinary medicine of small animals, considering diagnosis, follow-up, and prognosis of myocardial or systemic diseases. The relevance of NT-proBNP is associated with sample stability, easy determination in laboratory, sensitivity, accuracy, and the possibility to analyze myocardial function. These advantages are specially important when NT-proBNP is compared with other cardiac biomarkers, mostly those that indicate the integrity of the myocardial cell. Fast NT-proBNP assays are marketed today and may be used in association with complementary tests. Together, these methods are an important source of information in differential diagnosis of heart and lung diseases as well in the early diagnosis of cardiopathy in dogs and cats, proving valuable tools in treatment and prognosis.
Collapse
|
2
|
Wang BH, Reisman S, Bailey M, Kompa A, Ayhan M, Krum H, Rice G. Peptidomic profiles of post myocardial infarction rats affinity depleted plasma using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass spectrometry. Clin Transl Med 2012; 1:11. [PMID: 23369288 PMCID: PMC3560977 DOI: 10.1186/2001-1326-1-11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2012] [Accepted: 06/15/2012] [Indexed: 11/23/2022] Open
Abstract
Background Despite major advances in drug development, effective cardiovascular therapies and suitable cardiovascular biomarkers remain limited. The aim of this study was to leverage mass spectrometry (MS) based peptide profiling strategies to identify changes that occur in peptidomic profiles of rat plasma following coronary artery ligation generated myocardial infarction (MI). Methods One week after MI, rats were randomized to receive either an ACE inhibitor (ramipril, Ram-1 mg/kg/day), or vehicle (Veh) for 12 weeks. Echocardiography and hemodynamic measurements were made before sacrifice and plasma collection. High abundance proteins were depleted with affinity capture before MS profiling. Differentially expressed peptide ions were identified using proprietary software (ClinProtTools). Results MI increased heart/body weight (18%), lung/body weight (56%), and left ventricular (LV) end diastolic pressure (LVEDP, 247%); and significantly reduced percentage fractional shortening (FS, 75%) and rate of pressure rise in the LV (dP/dtmax, 20%). Ram treatment significantly attenuated the changes in LVEDP (61%) and FS (27%). Analysis of MALDI-ToF generated mass spectra demonstrated that peptide ions 1271, 1878, 1955, 2041 and 2254 m/z were consistently decreased by Ram treatment (p < 0.001) and thus may be associated with the agent’s therapeutic effects. Among peptides that were significantly changed, synapsin-2, adenomatous polyposis coli protein and transcription factor jun-D were identified as significantly reduced by Ram treatment. Conclusions This approach allows us to screen for potential biomarkers in a window of the blood proteome that previously has been difficult to access. The data obtained from such an approach may potentially useful in prognosis, diagnosis, and monitoring of treatment response.
Collapse
Affiliation(s)
- Bing Hui Wang
- Centre for Clinical Research, University of Queensland, Bld 71/918, Royal Brisbane and Women's Hospital, Herston, QLD, 4032, Australia.
| | | | | | | | | | | | | |
Collapse
|
3
|
Dambinova SA, Hayes RL. Future Trends in Biomarker Immunoassay Development. BIOMARKERS FOR TRAUMATIC BRAIN INJURY 2012. [DOI: 10.1039/9781849734745-00200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The evaluation of specific biomarkers for assessment of TBI and other neurological conditions, development of an immunoassay, and its translation to clinical laboratories are discussed. This chapter provides brief information concerning interrelations between assay development, clinical indications, regulatory restrictions, and future trends in drug/test co-development for TBI biomarkers. The strategy of biomarker assay adaptation to personalized medicine is outlined.
Collapse
Affiliation(s)
- Svetlana A. Dambinova
- Kennesaw State University, Brain Biomarkers Laboratory 1000 Chastain Road, Kennesaw, GA 30144 USA
| | - Ronald L. Hayes
- Banyan Biomarkers 13400 Progress Blvd., Alachua, FL 32615 USA
| |
Collapse
|
4
|
|
5
|
Kaar G, Dieplinger B, Gabriel C, Haltmayer M, Mueller T. Proguanylin and prouroguanylin--assay evaluation and clinical analyte characterization. Clin Chim Acta 2011; 412:2277-83. [PMID: 21888901 DOI: 10.1016/j.cca.2011.08.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2011] [Revised: 08/14/2011] [Accepted: 08/15/2011] [Indexed: 11/28/2022]
Abstract
BACKGROUND The biomarkers proguanylin and prouroguanylin are members of the natriuretic peptide family. The aim of this study was to evaluate two commercially available assays for proguanylin and prouroguanylin and to further characterize both analytes in terms of important clinical features. METHODS We evaluated precision and linearity of the BioVendor human proguanylin and prouroguanylin ELISAs. In order to characterize both analytes, we tested in vitro analyte stabilities at -80 °C, and determined biological variability and reference values for proguanylin and prouroguanylin. RESULTS Within-run and total coefficients of variation were <10% for the BioVendor proguanylin and prouroguanylin assays. Both methods were linear across the tested measurement ranges. The analytes proguanylin and prouroguanylin were stable for at least 2 months at -80 °C. With respect to biological variability, the reference change values (RCV) were 27% and 59% for proguanylin and prouroguanylin, respectively. For proguanylin, age-independent reference values were 4.0-13.4 ng/mL in males and 4.6-16.3 ng/mL in females. For prouroguanylin, age- and sex-independent reference values were 2.1-11.2 ng/mL. CONCLUSION The BioVendor human proguanylin ELISA and the BioVendor human prouroguanylin ELISA meet the needs of quality specifications of laboratory medicine. The results of the characterization of both analytes provide essential information for further clinical studies.
Collapse
Affiliation(s)
- Gerhard Kaar
- Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria
| | | | | | | | | |
Collapse
|
6
|
Application of serum protein fingerprint in diagnosis of coronary artery disease. Clin Biochem 2011; 44:185-91. [DOI: 10.1016/j.clinbiochem.2010.10.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2010] [Revised: 10/04/2010] [Accepted: 10/06/2010] [Indexed: 11/24/2022]
|
7
|
Tai DF, Ho YF, Wu CH, Lin TC, Lu KH, Lin KS. Artificial-epitope mapping for CK-MB assay. Analyst 2011; 136:2230-3. [DOI: 10.1039/c0an00919a] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
8
|
Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J 2010; 160:583-94. [PMID: 20934551 DOI: 10.1016/j.ahj.2010.06.010] [Citation(s) in RCA: 114] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2010] [Accepted: 06/07/2010] [Indexed: 10/19/2022]
Abstract
The rapid evaluation of patients presenting with symptoms suggestive of an acute coronary syndrome is of great clinical relevance. Biomarkers have become increasingly important in this setting to supplement electrocardiographic findings and patient history because one or both can be misleading. Today, cardiac troponin is still the only marker used routinely in this setting due to its myocardial tissue specificity and sensitivity, as well as its established usefulness for therapeutic decision making. However, even current generation troponin assays have certain limitations such as insufficient sensitivity for diagnosing unstable angina. Novel high-sensitivity assays for cardiac troponin have the potential to overcome these limitations. Further studies are needed to answer some critical questions regarding the best cutoffs for diagnosis and risk assessment and the optimal work-up for rule-out of acute myocardial infarction. Other nonmyocardial tissue-specific markers might help in this setting. Myeloperoxidase, copeptin, and growth differentiation factor 15 reflect different aspects of the development of atherosclerosis or acute ischemia. Each has demonstrated impact in risk stratification of acute coronary syndromes. Limited data also show that copeptin may, when used together with cardiac troponin, improve the sensitivity for diagnosing acute myocardial infarction, and growth differentiation factor 15 may help in selection of patients that benefit from invasive therapy. Further evaluation is needed before these markers can be adopted routinely in clinical practice.
Collapse
|
9
|
Balducci S, Zanuso S, Nicolucci A, Fernando F, Cavallo S, Cardelli P, Fallucca S, Alessi E, Letizia C, Jimenez A, Fallucca F, Pugliese G. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2010; 20:608-617. [PMID: 19695853 DOI: 10.1016/j.numecd.2009.04.015] [Citation(s) in RCA: 337] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2009] [Revised: 03/05/2009] [Accepted: 04/23/2009] [Indexed: 01/14/2023]
Abstract
BACKGROUND AND AIMS We investigated the effect of different exercise modalities on high sensitivity-C reactive protein (hs-CRP) and other inflammatory markers in patients with type 2 diabetes and the metabolic syndrome. METHODS AND RESULTS Eighty-two patients were randomized into 4 groups: sedentary control (A); receiving counseling to perform low-intensity physical activity (B); performing prescribed and supervised high-intensity aerobic (C) or aerobic+resistance (D) exercise (with the same caloric expenditure) for 12 months. Evaluation of leisure-time physical activity and assessment of physical fitness, cardiovascular risk factors and inflammatory biomarkers was performed at baseline and every 3 months. Volume of physical activity increased and HbA(1c) decreased in Groups B-D. VO(2max), HOMA-IR index, HDL-cholesterol, waist circumference and albuminuria improved in Groups C and D, whereas strength and flexibility improved only in Group D. Levels of hs-CRP decreased in all three exercising groups, but the reduction was significant only in Groups C and D, and particularly in Group D. Changes in VO(2max) and the exercise modalities were strong predictors of hs-CRP reduction, independent of body weight. Leptin, resistin and interleukin-6 decreased, whereas adiponectin increased in Groups C and D. Interleukin-1β, tumor necrosis factor-α and interferon-γ decreased, whereas anti-inflammatory interleukin-4 and 10 increased only in Group D. CONCLUSION Physical exercise in type 2 diabetic patients with the metabolic syndrome is associated with a significant reduction of hs-CRP and other inflammatory and insulin resistance biomarkers, independent of weight loss. Long-term high-intensity (preferably mixed) training, in addition to daytime physical activity, is required to obtain a significant anti-inflammatory effect.
Collapse
Affiliation(s)
- S Balducci
- Metabolic Fitness Association, Monterotondo, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kavsak PA, Worster A, You JJ, Oremus M, Elsharif A, Hill SA, Devereaux PJ, MacRae AR, Jaffe AS. Identification of myocardial injury in the emergency setting. Clin Biochem 2010; 43:539-44. [PMID: 20026097 PMCID: PMC3569499 DOI: 10.1016/j.clinbiochem.2009.12.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Revised: 12/09/2009] [Accepted: 12/10/2009] [Indexed: 01/04/2023]
Abstract
Within the past decade, the use of biomarkers to detect myocardial injury in the emergency department (ED) has been given increasing prominence as evident by the numerous studies and guidelines documenting their use. This review details the scope of the clinical problem, the history of changes in the definition of myocardial infarction (MI) and the new approaches, as well as suggestions for using laboratory biomarkers in the early detection of MI in the ED.
Collapse
Affiliation(s)
- Peter A Kavsak
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Callipo L, Caruso G, Foglia P, Gubbiotti R, Samperi R, Laganà A. Immunoprecipitation on magnetic beads and liquid chromatography-tandem mass spectrometry for carbonic anhydrase II quantification in human serum. Anal Biochem 2010; 400:195-202. [PMID: 20123083 DOI: 10.1016/j.ab.2010.01.039] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2009] [Revised: 01/14/2010] [Accepted: 01/28/2010] [Indexed: 11/18/2022]
Abstract
In this study, a magnetic bead-based platform amenable to high-throughput protein carbonic anhydrase II (CA II) capture is presented. The key steps in this approach involved immunoaffinity purification of the target protein from serum followed by on-bead digestion with trypsin to release a surrogate peptide. This tryptic peptide was quantified by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) operating in multiple reaction monitoring acquisition mode. Using a synthetic peptide standard and a structural analogue free-labeled internal standard, the resulting concentration was stoichiometrically converted to CA II serum concentration. The analytical steps, such as preparation of immunobeads, protein capture, proteolysis, and calibration, were optimized. The method was validated in terms of recovery (77%), reproducibility (relative standard deviation [RSD]<12%), and method detection limit (0.5 pmol ml(-1)). The developed method was applied to determining the CA II in eight healthy subjects, and the concentration measured was 27.3 pmol ml(-1) (RSD = 65%).
Collapse
Affiliation(s)
- Luciano Callipo
- Department of Chemistry, Sapienza University of Rome, 00185 Roma, Italy
| | | | | | | | | | | |
Collapse
|
12
|
Inter-individual variation in expression: a missing link in biomarker biology? Trends Biotechnol 2009; 27:5-10. [DOI: 10.1016/j.tibtech.2008.10.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2008] [Revised: 09/25/2008] [Accepted: 10/01/2008] [Indexed: 11/22/2022]
|
13
|
Goetze JP, Dahlström U, Rehfeld JF, Alehagen U. Impact of Epitope Specificity and Precursor Maturation in Pro-B–Type Natriuretic Peptide Measurement. Clin Chem 2008; 54:1780-7. [DOI: 10.1373/clinchem.2008.105635] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
AbstractBackground: Cardiac-derived natriuretic peptides are sensitive plasma markers of cardiac dysfunction. Recent reports have disclosed a more complex molecular heterogeneity of B-type natriuretic peptide precursor (proBNP)-derived peptides than previously suggested. In this study, we examined the impact of epitope specificity and precursor maturation on plasma measurement of proBNP-derived peptides.Methods: We compared 2 assays, N-terminal proBNP and proBNP 1–76, in a randomly collected set of human plasma specimens (n = 370). Additionally, we evaluated the clinical performance of 4 assays with different epitope specificities in a cohort of elderly patients presenting with symptoms associated with heart failure (n = 415).Results: Comparison of N-terminal proBNP with proBNP 1–76 measurement in plasma revealed a high correlation on regression analysis (r2 = 0.91, P < 0.0001). Nevertheless, the proBNP 1–76 assay measured lower concentrations in the high range than the N-terminal proBNP assay. Correlations between assay measurements in a clinical setting were comparable for all the assays (r2 approximately 0.57–0.83), and ROC analyses revealed area-under-the-curve values ranging between 0.77 and 0.81 for identifying reduced left ventricular ejection fraction. In parallel, all assays displayed comparable abilities in predicting long-term mortality.Conclusions: Our results reveal marked assay differences in analytical assay comparison, contrasting the overall comparable clinical performance in cardiovascular diagnostics or prognosis in the elderly.
Collapse
Affiliation(s)
- Jens Peter Goetze
- Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Denmark
| | - Ulf Dahlström
- Department of Cardiology, Linkoping University Hospital, Sweden
| | - Jens F Rehfeld
- Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Denmark
| | - Urban Alehagen
- Department of Cardiology, Linkoping University Hospital, Sweden
| |
Collapse
|
14
|
Edwards AV, White MY, Cordwell SJ. The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery. Mol Cell Proteomics 2008; 7:1824-37. [DOI: 10.1074/mcp.r800007-mcp200] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
15
|
Prasad A, Rihal CS, Lennon RJ, Singh M, Jaffe AS, Holmes DR. Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2008; 1:10-9. [DOI: 10.1161/circinterventions.108.765610] [Citation(s) in RCA: 148] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Myonecrosis after percutaneous coronary intervention (PCI) has been correlated with a worse prognosis, but controversy exists about the clinical significance and potential mechanisms for the association. The aim of this study was to evaluate the relative impact of preprocedural and postprocedural cardiac troponin T (cTnT) levels on survival rate after PCI.
Methods and Results—
We evaluated 5487 patients from the Mayo Clinic registry who required nonemergency PCI, and we examined the relationship between periprocedural cTnT levels, with the 99th percentile cutoff value used for normal (<0.01 ng/mL), and outcomes. The patients were divided into 3 groups: normal preprocedural and postprocedural cTnT levels (no myonecrosis), normal preprocedural but elevated postprocedural cTnT levels (PCI-related myonecrosis), and abnormal preprocedural cTnT. The 30-day death rates were 0.1%, 0.6%, and 2.3%, respectively, in the 3 groups. In a multivariable model, an abnormal pre-PCI cTnT level (hazard ratio 9.66 [2.30–40.57];
P
=0.002), and PCI-related myonecrosis (4.71 [1.02–21.83];
P
=0.048) were independent predictors of 30-day mortality. Over a median follow-up of 28 months, an abnormal pre-PCI cTnT level (hazard ratio 1.79 [1.35–2.39];
P
<0.001) independently predicted death, but the occurrence of PCI-related myonecrosis did not. A postprocedural elevation in creatine kinase MB fraction was not an independent predictor of long-term risk of death (0.912 [0.70–1.19];
P
=0.5).
Conclusions—
A preprocedural cTnT level >0.01 is a powerful independent predictor of prognosis after PCI and is of greater prognostic significance than the postprocedural biomarker levels. PCI-related myonecrosis occurs frequently and predicts short-term but not long-term risk of death.
Collapse
Affiliation(s)
- Abhiram Prasad
- From the Division of Cardiovascular Diseases and Department of Internal Medicine (A.P., C.S.R., M.S., A.S.J., D.R.H.) and Section of Biostatistics (R.J.L.), Mayo Clinic and Mayo Foundation, Rochester, Minn
| | - Charanjit S. Rihal
- From the Division of Cardiovascular Diseases and Department of Internal Medicine (A.P., C.S.R., M.S., A.S.J., D.R.H.) and Section of Biostatistics (R.J.L.), Mayo Clinic and Mayo Foundation, Rochester, Minn
| | - Ryan J. Lennon
- From the Division of Cardiovascular Diseases and Department of Internal Medicine (A.P., C.S.R., M.S., A.S.J., D.R.H.) and Section of Biostatistics (R.J.L.), Mayo Clinic and Mayo Foundation, Rochester, Minn
| | - Mandeep Singh
- From the Division of Cardiovascular Diseases and Department of Internal Medicine (A.P., C.S.R., M.S., A.S.J., D.R.H.) and Section of Biostatistics (R.J.L.), Mayo Clinic and Mayo Foundation, Rochester, Minn
| | - Allan S. Jaffe
- From the Division of Cardiovascular Diseases and Department of Internal Medicine (A.P., C.S.R., M.S., A.S.J., D.R.H.) and Section of Biostatistics (R.J.L.), Mayo Clinic and Mayo Foundation, Rochester, Minn
| | - David R. Holmes
- From the Division of Cardiovascular Diseases and Department of Internal Medicine (A.P., C.S.R., M.S., A.S.J., D.R.H.) and Section of Biostatistics (R.J.L.), Mayo Clinic and Mayo Foundation, Rochester, Minn
| |
Collapse
|
16
|
Hawkins RC. Difference between Abbott AxSYM BNP and Triage BNP (Beckman Coulter DxI 800) concentrations. Clin Chim Acta 2008; 393:134. [DOI: 10.1016/j.cca.2008.03.030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2008] [Revised: 03/19/2008] [Accepted: 03/19/2008] [Indexed: 10/22/2022]
|
17
|
Heyduk E, Dummit B, Chang YH, Heyduk T. Molecular pincers: antibody-based homogeneous protein sensors. Anal Chem 2008; 80:5152-9. [PMID: 18491925 PMCID: PMC2631435 DOI: 10.1021/ac8004154] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We describe here a new homogeneous antibody-based protein sensor design (molecular pincers) that allows rapid and sensitive detection of a specific protein in solution. In the presence of the target protein these sensors produce fluorescence signal derived from target-dependent annealing of short complementary fluorochrome-labeled oligonucleotides attached to a pair of target-specific antibodies via nanometer-scale flexible linkers. The sensors allow near-instantaneous detection of the target with sensitivity and specificity approaching that of enzyme-linked immunosorbent assay (ELISA) but requiring no sample manipulation other then the addition of the sample to the sensor mix. We used cardiac troponin I and C-reactive protein as the targets to validate these desirable properties of the sensors. Due to the availability of antibodies to thousands of interesting targets and the straightforward design blueprint of the sensors we expect their wide-ranging applications in research and medical diagnosis, especially when simplicity, high throughput, and short detection time are essential.
Collapse
Affiliation(s)
- Ewa Heyduk
- Edward A. Doisy Department of Biochemistry and Molecular Biology, St. Louis University Medical School, 1100 South Grand Boulevard, St. Louis, Missouri 63104, USA.
| | | | | | | |
Collapse
|
18
|
Cavaliere C, Cucci F, Guarino C, Gubbiotti R, Samperi R, Laganà A. Absolute quantification of cardiac troponin T by means of liquid chromatography/triple quadrupole tandem mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2008; 22:1159-1167. [PMID: 18338372 DOI: 10.1002/rcm.3495] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A liquid chromatography/tandem mass spectrometric method for absolute quantification of cardiac troponin T (cTnT) in mouse heart tissue is presented. Even in such a complex biological sample, the multiple reaction monitoring acquisition mode allowed the selective and sensitive determination of a specific peptide, obtained by cTnT enzymatic digestion. The concentration of this cTnT-specific peptide was considered as a representation of the concentration of its parent protein. Quantification was carried out by means of the matrix-matched calibration curve, constructed by adding the synthetic standard of the target peptide and another synthetic structurally analogous peptide as internal standard. Method identification limit and method quantification limit were estimated as 60 and 110 ng of cTnT per mg of total extracted proteins, respectively. The developed label-free approach has been applied for the absolute quantitation of cTnT because of its diagnostic and prognostic value as cardiac disease marker. However, the method could be of general application, since it requires only the synthesis of two suitable peptides, a protein tryptic cleavage product and an internal standard.
Collapse
Affiliation(s)
- Chiara Cavaliere
- Department of Chemistry, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome, Italy
| | | | | | | | | | | |
Collapse
|
19
|
Kavsak PA, Ko DT, Newman AM, Palomaki GE, Lustig V, Macrae AR, Jaffe AS. "Upstream markers" provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. Clin Chim Acta 2007; 387:133-8. [PMID: 17964560 DOI: 10.1016/j.cca.2007.09.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2007] [Revised: 09/24/2007] [Accepted: 09/26/2007] [Indexed: 11/15/2022]
Abstract
BACKGROUND For patients presenting with acute coronary syndrome (ACS) to the emergency department, early identification of those that are at high risk for subsequent myocardial necrosis or adverse outcomes would allow earlier or more aggressive treatment. We determined if a panel of biomarkers can be used to identify high risk patients. METHODS A cohort (84 females/132 males) from our 1996 ACS study population that had EDTA specimens stored (-70 degrees C) was selected and the earliest available specimen was analyzed for 11 biomarkers (IL-6, IL-8, MCP-1, VEGF, L-selectin, P-selectin, E-selectin, ICAM-1, VCAM-1, NT-proBNP, cTnT). These data were linked to the existing cTnI and health outcome databases for this population. ROC curve analysis for myocardial necrosis (i.e., peak cTnI >0.04 microg/l) identified 3 candidate biomarkers. These 3 biomarkers were applied together to generate a panel test (2 of the 3 biomarkers increased for a positive result) and assessed for its ability to identify patients at risk for myocardial necrosis and the combined endpoint of death, myocardial infarction (MI) and heart failure (HF). RESULTS The panel test (IL-6, NT-proBNP, E-selectin) alone detected 60% (95% CI: 49-69; false positive rate: 26%) of subjects that would be classified with myocardial necrosis. Kaplan-Meier and Cox proportional analyses indicated that patients positive by the biomarker panel (including those with cTnI < or =0.04 microg/l) had significantly worse outcomes (death/MI/HF) as compared to those negative by both cTnI and the panel test. CONCLUSION A biomarker panel analyzed early after pain onset can identify individuals at risk for both myocardial necrosis and the combined endpoint of death/MI/HF. Additional prospective studies are required to assess this panel for both early MI detection and to further refine which health outcomes (death, MI, HF) are associated with positive panel results.
Collapse
Affiliation(s)
- Peter A Kavsak
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
| | | | | | | | | | | | | |
Collapse
|